CoChat

SAGE-217, a novel GABAA receptor positive allosteric modulator: clinical pharmacology and tolerability in randomized phase i dose-finding studies.

Open access

The DOI matches its Crossref record; 30 of the 30 references it cites were found in a registry or an index.

Abstract

SAGE-217, a novel γ-aminobutyric acid A (GABA A ) receptor positive allosteric modulator, was evaluated in phase I, double-blind, placebo-controlled, single ascending dose (SAD) and multiple ascending dose (MAD) studies to assess the safety and pharmacokinetics (PK) of SAGE-217 following administration as an oral solution. In the SAD study, subjects were randomized 6:2 to a single dose of SAGE-217 or placebo. Doses ranged from 0.25 to 66 mg across nine cohorts. In the MAD study, subjects were randomized 9:3 and received SAGE-217 (15, 30, or 35 mg) or placebo once daily for 7 days. In both studies, PK, maximum tolerated dose (MTD; against predetermined criteria), safety, and tolerability were assessed. A total of 108 healthy volunteers enrolled in the studies—72 subjects in the SAD study and 36 subjects in the MAD study. SAGE-217 was orally bioavailable, with a terminal-phase half-life of 16–23 h and a t max of approximately 1 h. The MTDs for the oral solution of SAGE-217 in the SAD and MAD studies were determined to be 55 and 30 mg daily, respectively. In both studies, SAGE-217 was generally well tolerated, and no serious adverse events (SAEs) were reported. Most AEs were mild, dose-dependent, transient, occurred around the t max , and related to drug pharmacology. SAGE-217 was generally well tolerated, and its PK profile was well characterized. Based on this profile, SAGE-217 has been advanced into multiple phase II clinical programs and pivotal studies of major depressive disorder and postpartum depression.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1007/s40262-019-00801-0

Cites

30 of 30 references verified0 citation errors · 0 not checkable

Statistics

Figures

Fig. 1 a SAGE-217 plasma concentration over time (SAD). Mean plasma concentration of SAGE-217 by dose over time (n = 6 for each dose). b SAGE-217 plasma concentration over time (MAD). Mean plasma concentration of SAGE-217 by dose over time; day 7 dosing (n = 9 for each dose). SAD single ascending dose, MAD multiple ascending dose
Fig. 1 a SAGE-217 plasma concentration over time (SAD). Mean plasma concentration of SAGE-217 by dose over time (n = 6 for each dose). b SAGE-217 plasma concentration over time (MAD). Mean plasma concentration of SAGE-217 by dose over time; day 7 dosing (n = 9 for each dose). SAD single ascending dose, MAD multiple ascending doseCC BY-NC · PubMed Central
Fig. 2 Dose proportionality and linearity in the SAD and MAD studies. Combined data from the SAD and MAD studies was used to assess dose linearity. a AUC∞ over SAGE-217 dose. bCmax over SAGE-217 dose. SAD single ascending dose, MAD multiple ascending dose, AUC∞ area under the concentration–time curve from the time of dosing extrapolated to infinity, Cmax maximum concentration
Fig. 2 Dose proportionality and linearity in the SAD and MAD studies. Combined data from the SAD and MAD studies was used to assess dose linearity. a AUC∞ over SAGE-217 dose. bCmax over SAGE-217 dose. SAD single ascending dose, MAD multiple ascending dose, AUC∞ area under the concentration–time curve from the time of dosing extrapolated to infinity, Cmax maximum concentrationCC BY-NC · PubMed Central
Fig. 3 Mean SSS and MOAA/S scale scores during the MAD study. Mean a SSS and b MOAA/S values for the placebo group (N = 9) and the 30 mg morning group (N = 9; maximum tolerable dose). SSS Stanford Sleepiness Scale, MOAA/S Modified Observer’s Assessment of Alertness/Sedation, MAD multiple ascending dose
Fig. 3 Mean SSS and MOAA/S scale scores during the MAD study. Mean a SSS and b MOAA/S values for the placebo group (N = 9) and the 30 mg morning group (N = 9; maximum tolerable dose). SSS Stanford Sleepiness Scale, MOAA/S Modified Observer’s Assessment of Alertness/Sedation, MAD multiple ascending doseCC BY-NC · PubMed Central

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 30 references

Cited by

See all 63

Metadata

Authors
Hoffmann, E., Nomikos, G. G., Kaul, I., Raines, S., Wald, J., Bullock, A., Sankoh, A. J., Doherty, J., Kanes, S. J., & Colquhoun, H.
Affiliations
  • Sage Therapeutics (United States) (US)
  • Biogen (United States) (US)
Corresponding author
Hoffmann, Ethan
Venue
Clinical Pharmacokinetics
Published
2019-07-24
Volume
59
Issue
1
Pages
111-120
ISSN
  • 0312-5963 (ISSN-L)
  • 1179-1926
OpenAlex
W2963972855
Cited by
59
References
30
Citations by year
2026: 1 · 2025: 4 · 2024: 18 · 2023: 14 · 2022: 5 · 2021: 7 · 2020: 7 · 2019: 3
FWCI
2.63
Type
journal article
Language
en
Open access
Licence
Locations
  • Clinical Pharmacokinetics (publishedVersion, cc-by-nc)
  • Europe PMC (PubMed Central) (publishedVersion, cc-by-nc)
  • PubMed Central (publishedVersion, cc-by-nc)
  • PubMed (publishedVersion)
Funders
Sage Therapeutics, Inc.
Topics
  • Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Neuroscience and Neuropharmacology Research
  • Health Sciences › Medicine › Clinical Neurology › Epilepsy research and treatment
  • Health Sciences › Medicine › Pediatrics, Perinatology and Child Health › Pharmaceutical studies and practices
Keywords
GABAA receptor, positive allosteric modulators, pharmacokinetics, tolerability, maximum tolerated dose, dose-finding, healthy volunteers, major depressive disorder, postpartum depression, oral bioavailability
MeSH terms
Administration, Oral, Adult, Allosteric Regulation, Major Depressive Disorder, Dose-Response Relationship, Drug, Double-Blind Method, Drug Administration Schedule, Female, Humans, Male, Middle Aged, Pharmacology, Clinical, Placebos, Pregnanes, Pregnanolone, Pyrazoles, Safety, Depression, Postpartum, GABA-A Receptor Agonists, Healthy Volunteers

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: SAGE-217, a novel GABAA receptor positive allosteric modulator: clinical pharmacology and tolerability in randomized phase i dose-finding studies. https://app.cochat.ai/papers/10.1007/s40262-019-00801-0
The paper
Hoffmann, E., Nomikos, G. G., Kaul, I., Raines, S., Wald, J., Bullock, A., Sankoh, A. J., Doherty, J., Kanes, S. J., & Colquhoun, H. (2020). SAGE-217, a novel GABAA receptor positive allosteric modulator: clinical pharmacology and tolerability in randomized phase i dose-finding studies. Clinical Pharmacokinetics. https://doi.org/10.1007/s40262-019-00801-0

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.